Literature DB >> 12152998

Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea.

Hana Bruchova1, Tereza Borovanova, Hana Klamova, Radim Brdicka.   

Abstract

Using array technology that allows the simultaneous detection of gene expression of hundreds of genes, four patients with chronic myeloid leukemia (CML) were investigated at diagnosis and after starting administration of hydroxyurea. To detect the gene expression of peripheral blood mononuclears and granulocytes Human Cancer cDNA Array (CLONTECH) with 588 gene probes was used. Gene expression mononuclear and granulocyte profiles of patients at diagnosis were compared with the control profiles. The significant expression changes observed in most patients seemed to be important. Increased expression of c-jun N-terminal kinase 2 (JNK2), integrin alpha E, MMP-8, MMP-9 was detected in both fractions of most patients. In some samples PCNA, HDGF, MAPK p38, CD59 increased expressions were found. Significant down-regulation of expression in patients was detected in genes CDK4 inhibitor A, PURA, notch1 in mononuclears; STAT2, STAT5, RAR-alpha, MCL-1, junB, caspase 4 in granulocytes; CDK6, GADD153, ERBB-3, cadherin 5 in both fractions. Expression profiles detected in patients at diagnosis did not differ markedly from those after one-week treatment with hydroxyurea. Only in a few genes were significant changes after hydroxyurea administration observed and inter-individual expression differences were rather common.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152998     DOI: 10.1080/10428190290026358

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.

Authors:  Q Li; Y Wu; S Fang; L Wang; H Qi; Y Zhang; J Zhang; W Li
Journal:  Cancer Gene Ther       Date:  2015-04-03       Impact factor: 5.987

2.  Targeting of gene expression by siRNA in CML primary cells.

Authors:  Michaela Merkerova; Hana Klamova; Radim Brdicka; Hana Bruchova
Journal:  Mol Biol Rep       Date:  2006-11-09       Impact factor: 2.316

3.  JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.

Authors:  Rosa Farràs; Véronique Baldin; Sandra Gallach; Claire Acquaviva; Guillaume Bossis; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2008-04-07       Impact factor: 4.272

Review 4.  Leukemic stem cells: where do they come from?

Authors:  Emmanuelle Passegué; Irving L Weisman
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

5.  Molecular biological characteristics of the recruitment of hematopoietic stem cells from bone marrow niche in chronic myeloid leukemia.

Authors:  Biao Zhu; Jianbo Zhang; Jiao Chen; Chenglong Li; Xiaodong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia.

Authors:  Xishan Zhu; Ziying Lin; Jing Du; Xu Zhou; Lawei Yang; Gang Liu
Journal:  Mol Cell Biochem       Date:  2014-01-03       Impact factor: 3.396

Review 7.  Multiple roles for Puralpha in cellular and viral regulation.

Authors:  Martyn K White; Edward M Johnson; Kamel Khalili
Journal:  Cell Cycle       Date:  2009-02-10       Impact factor: 4.534

8.  Protective role of Puralpha to cisplatin.

Authors:  Rafal Kaminski; Armine Darbinyan; Nana Merabova; Satish L Deshmane; Martyn K White; Kamel Khalili
Journal:  Cancer Biol Ther       Date:  2008-12-08       Impact factor: 4.742

9.  Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.

Authors:  Koyu Hoshino; Alfonso Quintás-Cardama; Jerald Radich; Hongyui Dai; Hui Yang; Guillermo Garcia-Manero
Journal:  Leuk Res       Date:  2009-05-05       Impact factor: 3.156

10.  Role of Puralpha in the modulation of homologous recombination-directed DNA repair by HIV-1 Tat.

Authors:  Huichen Wang; Martyn K White; Rafal Kaminski; Nune Darbinian; Shohreh Amini; Edward M Johnson; Kamel Khalili; Jay Rappaport
Journal:  Anticancer Res       Date:  2008 May-Jun       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.